Dr. Lichtman’s research focuses is in the area of behavioral pharmacology, with an emphasis on the investigation of the endogenous cannabinoid system. His NIDA-supported research has resulted in the publication of over 150 peer-review articles that have revealed: 1) the physiological functions of the endocannabinoid system; 2) the neural substrates and mechanisms of action underlying cannabinoid-induced behaviors; and 3) the consequences of chronic cannabinoid administration (i.e., dependence). His research utilizes a collaborative multidisciplinary approach examining the relationship between the pharmacological effects of cannabinoids on behavior and the underlying biochemical/molecular processes. His research group has provided proof of principle that the endogenous cannabinoid system can be harnessed to modulate drug dependence, pain and inflammation, and extinction of aversive memories. The long-term goal of the Lichtman research program is to increase understanding of the physiological functions of the endogenous cannabinoid system and to contribute to the development of cannabinoid-based medications for the treatment of pain and inflammatory disorders, psychiatric disorders and drug addiction.

 Dr. Lichtman’s research focuses is in the area of behavioral pharmacology, with an emphasis on the investigation of the endogenous cannabinoid system. His NIDA-supported research has resulted in the publication of over 150 peer-review articles that have revealed: 1) the physiological functions of the endocannabinoid system; 2) the neural substrates and mechanisms of action underlying cannabinoid-induced behaviors; and 3) the consequences of chronic cannabinoid administration (i.e., dependence). His research utilizes a collaborative multidisciplinary approach examining the relationship between the pharmacological effects of cannabinoids on behavior and the underlying biochemical/molecular processes. His research group has provided proof of principle that the endogenous cannabinoid system can be harnessed to modulate drug dependence, pain and inflammation, and extinction of aversive memories. The long-term goal of the Lichtman research program is to increase understanding of the physiological functions of the endogenous cannabinoid system and to contribute to the development of cannabinoid-based medications for the treatment of pain and inflammatory disorders, psychiatric disorders and drug addiction.